{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:11:51Z","timestamp":1790233911721,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The Ki-67\/MIB-1 labeling index (LI) is clinically used to differentiate between high and low-grade gliomas, while its prognostic value remains questionable. Glioblastoma (GBM) expressing wild-type isocitrate dehydrogenase IDH\n                      <jats:sup>wt<\/jats:sup>\n                      , a relatively common malignant brain tumor in adults, is characterized by a dismal prognosis. Herein, we have retrospectively investigated the prognostic role of Ki-67\/MIB-1-LI in a large group of IDH\n                      <jats:sup>wt<\/jats:sup>\n                      GBM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      One hundred nineteen IDH\n                      <jats:sup>wt<\/jats:sup>\n                      GBM patients treated with surgery followed by Stupp\u2019s protocol in our Institution between January 2016 and December 2021 were selected. A cut-off value for Ki-67\/MIB-1-LI was used with minimal p-value based approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A multivariate analysis showed that Ki-67\/MIB-1-LI expression\u2009&lt;\u200915% significantly correlated with a longer overall survival (OS), independently from the age of the patients, Karnofsky performance status scale, extent of surgery and O\n                      <jats:sup>6<\/jats:sup>\n                      -methylguanine (O6-MeG)-DNA methyltransferase promoter methylation status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Among other studies focused on Ki-67\/MIB-1-LI, this is the first observational study showing a positive correlation between OS of IDH\n                      <jats:sup>wt<\/jats:sup>\n                      GBM patients and Ki-67\/MIB-1-LI that we propose as a new predictive marker in this subtype of GBM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-023-04342-2","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:01:38Z","timestamp":1684976498000},"page":"339-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Low expression of Ki-67\/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status"],"prefix":"10.1007","volume":"163","author":[{"given":"Paolo","family":"Tini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Yavoroska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Miracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Pirtoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Tomaciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marampon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"4342_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4342_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/nop\/npac026","volume":"9","author":"A Wu","year":"2022","unstructured":"Wu A, Ugiliweneza B, Wang D et al (2022) Trends and outcomes of early and late palliative care consultation for adult patients with glioblastoma: a seer-medicare retrospective study. Neurooncol Pract 9:299\u2013309. https:\/\/doi.org\/10.1093\/nop\/npac026","journal-title":"Neurooncol Pract"},{"key":"4342_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"4342_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"4342_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 360:765\u2013773. https:\/\/doi.org\/10.1056\/NEJMoa0808710","journal-title":"N Engl J Med"},{"key":"4342_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130596","author":"A Amelot","year":"2015","unstructured":"Amelot A, De Cremoux P, Quillien V et al (2015) IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0130596","journal-title":"PLoS ONE"},{"key":"4342_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","volume":"11","author":"LT Li","year":"2015","unstructured":"Li LT, Jiang G, Chen Q, Zheng JN (2015) Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep 11:1566\u20131572. https:\/\/doi.org\/10.3892\/mmr.2014.2914","journal-title":"Mol Med Rep"},{"key":"4342_CR8","first-page":"2717","volume":"15","author":"SM Veronese","year":"1995","unstructured":"Veronese SM, Maisano C, Scibilia J (1995) Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 15:2717\u20132722","journal-title":"Anticancer Res"},{"key":"4342_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4103\/0973-1482.139154","volume":"10","author":"M Thotakura","year":"2014","unstructured":"Thotakura M, Tirumalasetti N, Krishna R (2014) Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Cancer Res Ther 10:641. https:\/\/doi.org\/10.4103\/0973-1482.139154","journal-title":"J Cancer Res Ther"},{"key":"4342_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11060-005-5262-1","volume":"76","author":"SI Moskowitz","year":"2006","unstructured":"Moskowitz SI, Jin T, Prayson RA (2006) Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 76:193\u2013200. https:\/\/doi.org\/10.1007\/s11060-005-5262-1","journal-title":"J Neurooncol"},{"key":"4342_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7314\/APJCP.2015.16.2.411","volume":"16","author":"W-J Chen","year":"2015","unstructured":"Chen W-J, He D-S, Tang R-X et al (2015) Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pac J Cancer Prev 16:411\u2013420. https:\/\/doi.org\/10.7314\/APJCP.2015.16.2.411","journal-title":"Asian Pac J Cancer Prev"},{"key":"4342_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/a:1013845004294","volume":"55","author":"JF Reavey-Cantwell","year":"2001","unstructured":"Reavey-Cantwell JF, Haroun RI, Zahurak M et al (2001) The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 55:195\u2013204. https:\/\/doi.org\/10.1023\/a:1013845004294","journal-title":"J Neurooncol"},{"key":"4342_CR13","doi-asserted-by":"publisher","first-page":"17918","DOI":"10.1038\/s41598-021-95958-9","volume":"11","author":"RH Dahlrot","year":"2021","unstructured":"Dahlrot RH, Bangs\u00f8 JA, Petersen JK et al (2021) Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. Sci Rep 11:17918. https:\/\/doi.org\/10.1038\/s41598-021-95958-9","journal-title":"Sci Rep"},{"key":"4342_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ajco.12826","volume":"15","author":"E Wong","year":"2019","unstructured":"Wong E, Nahar N, Hau E et al (2019) Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma. Asia Pac J Clin Oncol 15:5\u20139. https:\/\/doi.org\/10.1111\/ajco.12826","journal-title":"Asia Pac J Clin Oncol"},{"key":"4342_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/1553408","volume":"2023","author":"Z Yu","year":"2023","unstructured":"Yu Z, Zhou Z, Xu M et al (2023) Prognostic factors of gliosarcoma in the real world: a retrospective cohort study. Comput Math Methods Med 2023:1\u201314. https:\/\/doi.org\/10.1155\/2023\/1553408","journal-title":"Comput Math Methods Med"},{"key":"4342_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106726","author":"N Kumar","year":"2021","unstructured":"Kumar N, Elangovan A, Madan R et al (2021) Impact of Immunohistochemical profiling of glioblastoma multiforme on clinical outcomes: real-world scenario in resource limited setting. Clin Neurol Neurosurg. https:\/\/doi.org\/10.1016\/j.clineuro.2021.106726","journal-title":"Clin Neurol Neurosurg"},{"key":"4342_CR17","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/j.wneu.2021.01.103","volume":"149","author":"VS Madhugiri","year":"2021","unstructured":"Madhugiri VS, Moiyadi AV, Shetty P et al (2021) Analysis of factors associated with long-term survival in patients with glioblastoma. World Neurosurg 149:e758\u2013e765. https:\/\/doi.org\/10.1016\/j.wneu.2021.01.103","journal-title":"World Neurosurg"},{"key":"4342_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12885-019-6511-6","volume":"20","author":"J Liang","year":"2020","unstructured":"Liang J, Lv X, Lu C et al (2020) Prognostic factors of patients with gliomas \u2013 an analysis on 335 patients with glioblastoma and other forms of gliomas. BMC Cancer 20:35. https:\/\/doi.org\/10.1186\/s12885-019-6511-6","journal-title":"BMC Cancer"},{"key":"4342_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S0959-8049(02)00065-5","volume":"38","author":"M Bredel","year":"2002","unstructured":"Bredel M, Piribauer M, Marosi C et al (2002) High expression of DNA topoisomerase II\u03b1 and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer 38:1343\u20131347. https:\/\/doi.org\/10.1016\/S0959-8049(02)00065-5","journal-title":"Eur J Cancer"},{"key":"4342_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00066-022-01959-6","volume":"198","author":"R Dumke","year":"2022","unstructured":"Dumke R, Dumke C, Eberle F et al (2022) Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy. Strahlenther Onkol 198:892\u2013906. https:\/\/doi.org\/10.1007\/s00066-022-01959-6","journal-title":"Strahlenther Onkol"},{"key":"4342_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.hemonc.2018.11.001","volume":"12","author":"A Alkhaibary","year":"2019","unstructured":"Alkhaibary A, Alassiri AH, AlSufiani F, Alharbi MA (2019) Ki-67 labeling index in glioblastoma; does it really matter? Hematol Oncol Stem Cell Ther 12:82\u201388. https:\/\/doi.org\/10.1016\/j.hemonc.2018.11.001","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"4342_CR22","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"4342_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105445","author":"P Tini","year":"2019","unstructured":"Tini P, Nardone V, Pastina P et al (2019) Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? Clin Neurol Neurosurg. https:\/\/doi.org\/10.1016\/j.clineuro.2019.105445","journal-title":"Clin Neurol Neurosurg"},{"key":"4342_CR24","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-Tile. Clin Cancer Res 10:7252\u20137259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713","journal-title":"Clin Cancer Res"},{"key":"4342_CR25","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/brain\/awm204","volume":"130","author":"D Krex","year":"2007","unstructured":"Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596\u20132606. https:\/\/doi.org\/10.1093\/brain\/awm204","journal-title":"Brain"},{"key":"4342_CR26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/jnci\/djt306","volume":"105","author":"M-YC Polley","year":"2013","unstructured":"Polley M-YC, Leung SCY, McShane LM et al (2013) An international Ki67 reproducibility study. J Nat Cancer Inst 105:1897\u20131906. https:\/\/doi.org\/10.1093\/jnci\/djt306","journal-title":"J Nat Cancer Inst"},{"key":"4342_CR27","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/1097-0142(20011115)92:10<2720::AID-CNCR1626>3.0.CO;2-Z","volume":"92","author":"DM Grzybicki","year":"2001","unstructured":"Grzybicki DM, Liu Y, Moore SA et al (2001) Interobserver variability associated with the MIB-1 labeling index. Cancer 92:2720\u20132726. https:\/\/doi.org\/10.1002\/1097-0142(20011115)92:10%3c2720::AID-CNCR1626%3e3.0.CO;2-Z","journal-title":"Cancer"},{"key":"4342_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13000-018-0711-2","volume":"13","author":"LAG Nielsen","year":"2018","unstructured":"Nielsen LAG, Bangs\u00f8 JA, Lindahl KH et al (2018) Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. Diagn Pathol 13:38. https:\/\/doi.org\/10.1186\/s13000-018-0711-2","journal-title":"Diagn Pathol"},{"key":"4342_CR29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41379-021-00745-6","volume":"34","author":"TN Aung","year":"2021","unstructured":"Aung TN, Acs B, Warrell J et al (2021) A new tool for technical standardization of the Ki67 immunohistochemical assay. Mod Pathol 34:1261\u20131270. https:\/\/doi.org\/10.1038\/s41379-021-00745-6","journal-title":"Mod Pathol"},{"key":"4342_CR30","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1016\/j.wneu.2019.02.006","volume":"125","author":"C Henker","year":"2019","unstructured":"Henker C, Kriesen T, Schneider B et al (2019) Correlation of Ki-67 index with volumetric segmentation and its value as a prognostic marker in glioblastoma. World Neurosurg 125:e1093\u2013e1103. https:\/\/doi.org\/10.1016\/j.wneu.2019.02.006","journal-title":"World Neurosurg"},{"key":"4342_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00401-015-1427-y","volume":"130","author":"C Geisenberger","year":"2015","unstructured":"Geisenberger C, Mock A, Warta R et al (2015) Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19\/20 co-gain. Acta Neuropathol 130:419\u2013434. https:\/\/doi.org\/10.1007\/s00401-015-1427-y","journal-title":"Acta Neuropathol"},{"key":"4342_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106126","author":"D Armocida","year":"2020","unstructured":"Armocida D, Frati A, Salvati M et al (2020) Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation. Clin Neurol Neurosurg. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106126","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04342-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04342-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04342-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T04:06:28Z","timestamp":1688529988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04342-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4342"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04342-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2826545\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}